Browse studies

Find your next paid study

930 recruiting studies matching your filters

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, he…

Advanced/Metastatic Solid TumorsBladder CancerUrothelial Carcinoma+10 more

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

Estimated

~$10 – $8,750

Phase 2

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with…

Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05773274

Phase 2

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolli…

Advanced Solid TumorMelanomaHead and Neck Cancer+11 more

Estimated

~$10 – $7,500

Daiichi SankyoNCT06172478

Phase 1

A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic o…

Advanced Solid TumorMesothelioma, Malignant

Estimated

~$10 – $8,750

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT06251310

Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gath…

Non-Small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02146170

Phase 1

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancer…

Locally Advanced Solid TumorMetastatic Solid Tumor

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe…

Solid Tumor

Estimated

~$10 – $8,750

Astellas Pharma IncNCT05382559

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of ki…

Renal Tumor HistologyCutaneous LeiomyomaKidney Cancer

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00050752

Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, nec…

Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, Neuroendocrine+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06406465

DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in c…

Pleuropulmonary BlastomaCystic NephromaOvarian Sertoli-Leydig Cell Tumors+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01247597

Phase 1

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. T…

Solid Tumors

Estimated

~$10 – $7,500

Boehringer IngelheimNCT05471856